|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis显示文摘AIM:To search for the answer in extensive ulcerative colitis as to whether histological inflammation persisting despite endoscopic mucosal healing serves to increase the risk of colon cancer(CC)or high grade dysplasia(HGD).METHODS:This is a single center(Lenox Hill Hospital)retrospective cohort and descriptive study of extensive ulcerative colitis(UC)for 20 years or more with a minimum of 3 surveillance colonoscopies and biopsies performed after the first 10 years of UC diagnosis.Data analyzed included:duration of UC,date of diagnosis of(CC)or(HGD),number of surveillance colonoscopies,and biopsies showing histological inflammation and its severity in each of 6 segments when endoscopic appearance is normal.Two subgroups of patients were compared:group 1 patients who developed CC/HGD and group 2 patients who did not develop CC/HGD.RESULTS:Of 115 patients with longstanding UC reviewed,68 patients met the inclusion criteria.Twenty patients were in group 1 and 48 in group 2.We identified the number of times for each patient when the endoscopic appearance was normal but biopsies nevertheless showed inflammation.Overall,histological disease activity in the absence of gross/endoscopic disease was found in 31.2%(95%CI:28%-35%)of colonoscopies performed on the entire cohort of 68 patients.Histological disease activity when the colonoscopy showed an absence of gross disease activity was more common in group 1 than group 2 patients,88%(95%CI:72%-97%)vs 59%(95%CI:53%-64%).Only 3/20(15%)of patients in group 1 ever had a colonoscopy completely without demonstrated disease activity(i.e.,no endoscopic or histological activity)as compared to 37/48(77%)of patients in group 2,and only 3.3%(95%CI:0.09%-8.3%)of colonoscopies in group 1 had no histological inflammation compared to23%(95%CI:20%-27%)in group 2.CONCLUSION:Progression to HGD or CC in extensive ulcerative colitis of long standing was more frequently encountered among those patients who demonstrate persistent histological inflammation in the absence of gross mucosal disease.Our findings support including the elimination of histological inflammation in the definition of mucosal healing,and support this endpoint as an appropriate goal of therapy because of its risk of increasing dysplasia and colon cancer. | Burton I Korelitz Keith Sultan Megha Kothari Leo Arapos Judy Schneider Georgia Panagopoulos | 2014 | World Journal of Gastroenterology2014，20，17： | 4 |
| 2 | Choice of laxatives and colonoscopic preparation in pregnant patients from the viewpoint of obstetricians and gastroenterologists显示文摘AIM: To elucidate the preferences of gastroenterologists at our institution and compare them to those of obstetricians when making decisions in the pregnant patient, including which type of bowel preparations to use for ? exible sigmoidoscopy or colonoscopy, as well as which laxatives can be used safely. METHODS: Surveys were mailed to all attending gastroenterologists (n = 53) and obstetricians (n = 99) at our institution. Each survey consisted of the 14 most common laxative or motility agents used in pregnancy and inquired about the physician’s prescribing habits in the past as well as their willingness to prescribe each medication in the future. The survey also listed four common bowel preparations used prior to colonoscopy and sigmoidoscopy and asked the physician to rank the order of the preferred agent in each case. RESULTS: With regard to common laxatives, both gastroenterologists and obstetricians favor the use of Metamucil, Colace, and Citrucel. Both groups appear to refrain from using Fleets Phosphosoda and Castor oil. Of note, obstetricians are less inclined to use PEG solution and Miralax, which is not the case with gastroenterologists. In terms of comparing bowel preparations for colonoscopy, 50% of gastroenterologists prefer to use PEG solution and 50% avoid the use of Fleets Phosphosoda. Obstetricians seem to prefer Fleets Phosphosoda (20%) and tend to avoid the use of PEG solution (26%). With regard to bowel preparation for sigmoidoscopy, both groups prefer Fleets enema the most (51%), while magnesium citrate is used least often (38%). CONCLUSION: It is clear that preferences in the use ofbowel cleansing preparations between the two groups exist, but there have not been many case controlled human studies in the pregnant patient that give clear cut indications for using one versus another drug. In light of the challenge of performing controlled trials in pregnant women, more extensive surveys should be undertaken to gather a larger amount of data on physicians’ experiences and individual preferences. | Jeevan Vinod Jennifer Bonheur Burton I Korelitz Georgia Panagopoulos | 2007 | World Journal of Gastroenterology2007，13，48： | 4 |
| 3 | Abnormalities of uterine cervix in women with inflammatory bowel disease显示文摘AIM: To evaluate the prevalence of abnormalities of the uterine cervix in women with inflammatory bowel disease (IBD) when compared to healthy controls. METHODS: One hundred and sixteen patients with IBD [64 with Crohn’s disease (CD) and 52 with ulcerative colitis (UC)] were matched to 116 healthy controls by age (+/- 2 years) at the time of most recent papanicolaou (Pap) smear. Data collected consisted of age, race, marital status, number of pregnancies, abortions/miscarriages, duration and severity of IBD, Pap smear results within five years of enrollment, and treatment with immunosuppressive drugs. Pap smear results were categorized as normal or abnormal including atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LGSIL), and high-grade squamous intraepithelial lesion (HGSIL). RESULTS: The median age at the time of Pap smear was 46 (range: 17-74) years for the IBD group and matched controls (range: 19-72 years). There were more Caucasian subjects than other ethnicities in the IBD patient group (P = 0.025), as well as fewer abortions (P = 0.008), but there was no significant difference regarding marital status. Eighteen percent of IBD patients had abnormal Pap smears compared to 5% of controls (P = 0.004). Subgroup analysis of the IBD patients revealed no significant differences between CD and UC patients in age, ethnicity, marital status, number of abortions, disease severity, family history of IBD, or disease duration. No significant difference was observedin the number of abnormal Pap smears or the use of immunosuppressive medications between CD and UC patients (P = 0.793). No definitive observation could be made regarding HPV status, as this was not routinely investigated during the timeframe of our study. CONCLUSION: Diagnosis of IBD in women is related to an increased risk of abnormal Pap smear, while type of IBD and exposure to immunosuppressive medications are not. This has significant implications for women with IBD in that Pap smear screening protocols should be conscientiously followed, with appropriate investigation of abnormal results. | Jyoti Bhatia Jason Bratcher Burton Korelitz Katherine Vakher Shlomo Mannor Maria Shevchuk Gworgia Panagopoulos Adam Ofer Ecaterina Tamas Panayota Kotsali Oana Vele | 2006 | World Journal of Gastroenterology2006，12，38： | 3 |
| 4 | Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective显示文摘The use of thiopurines in inflammatory bowel disease(IBD) has been examined in numerous prospective, controlled trials, with a majority demonstrating a clinical benefit. We conducted this review to describe the historical and current evidence in the use of thiopurines in IBD. A systematic search was performed on MEDLINE between 1965 and 2016 to identify studies on thiopurines in IBD. The most robust evidence for thiopurines in IBD includes induction of remission in combination with anti-tumor necrosis factor(antiTNF) agents, and maintenance of remission and postoperative maintenance in Crohn's disease. Less evidence exists for thiopurine monotherapy in induction of remission, maintenance of ulcerative colitis, chemoprevention of colorectal cancer, and in preventing immunogenicity to anti-TNF. Evidence was often limited by trial design. Overall, thiopurines have demonstrated efficacy in a broad range of presentations of IBD. With more efficacious novel therapeutic agents, the positioning of thiopurines in the management of IBD will change and future studies will analyze the benefit of thiopurines alone and in conjunction with these new medications. | Jordan E Axelrad Abhik Roy Garrett Lawlor Burton Korelitz Simon Lichtiger | 2016 | World Journal of Gastroenterology2016，22，46： | 3 |
| 5 | Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study显示文摘 | Joseph B Felder Burton I Korelitz Ramona Rajapakse Samuel Schwarz Angelo P Horatagis Gilbert Gleim | 2000 | The American Journal of Gastroenterology2000，，： | 1 |
| 6 | Expert opinion: Experience with 6-mercaptopurine in the treatment of inflammatory bowel disease显示文摘Arbitrarily, modern day treatment of inflammatory bowel disease begins with the introduction of immuno- suppressives for ulcerative colitis. Clinical improvement with sulfasalazine had been meaningful but modest. Treatment with adrenocorticotropic hormone and corti- costeroids led to clinical responses never before realized but it took much too long to recognize that they were not capable of maintaining remission, that adverse reactions were subtle but potentially devastating and that some other agent would be necessary to capitalize on their transient advantage. This of course was true in the treatment of Crohn's disease as well. Not much was ever made of the role of sulfasalazine for Crohn' s disease, but with the severing of the diazobond and the elimination of the sulphur component, the 5-ami- nosalacylic acid (5-ASA) products clearly led to clinical improvement, especially in cases of Crohn's colitis and those with ileitis where the 5-ASA product was released in the terminal ileum and more proximal in the small bowel as well as in ulcerative colitis. The induction of remission was first demonstrated by 6-mercaptopurine (6-MP) with case reports and uncontrolled trials in pa- tients with ulcerative colitis, but its placebo controlled trial for Crohn's disease firmly established its role in inducing remission. No subsequent trial has confirmed its similar role for ulcerative colitis, but nevertheless cli- nicians know well that 6-MP works at least as well and probably more effectively for ulcerative colitis than for Crohn's disease. What changes have taken place utiliz- ing 6-MP in the management of inflammatory bowel disease since its introduction in the 1960's and 1970's and its trial for Crohn's disease published in the New England Journal of Medicine in 1980? | Burton I Korelitz | 2013 | World Journal of Gastroenterology2013，19，20： | 1 |
| 7 | Increased risk of lymphoma a- mong inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine 显示文摘 | Kandiel A Fraser AG Korelitz BI | 2005 | Gut2005，54，8： | 1 |
| 8 | A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis显示文摘 | LOBEL EZ KORELITZ BI XUEREB MA | 2004 | Am J Gastroenterol2004，99，： | 1 |
| 9 | Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease显示文摘 | Ramona O Rajapakse Burton I Korelitz Jusuf Zlatanic Peter J Baiocco Gilbert W Gleim | 2000 | The American Journal of Gastroenterology2000，，： | 1 |
| 10 | The therapeutic efficacy of 6-mercaptopurine in refratory ulcerative colitis显示文摘 | ADLER DJ KORELITZ BI | 1990 | Am J Gastroenterol1990，85，： | 1 |
| 11 | The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children显示文摘 | Mofenson LM Korelitz J Meyer WA | 1997 | J Infect Dis1997，175，5： | 1 |
| 12 | Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease显示文摘 | KORELITZ BI ZLATANIC J GOEL F | 1999 | J Clin Gastroenterol1999，28，： | 1 |
| 13 | Significance of WBC differential whenleukopenia is induced by 6-MP for IBD显示文摘 | Korelitz BI Zlatanic J Smith MJ | 1997 | Gastroenterology1997，113，5： | 1 |
| 14 | Segmental sigmoid polyposis as a colonoscopic indicator of an ileosigmoid fistula in Crohn's ileitis 显示文摘 | Korelitz BI Taunk R Kesar V | 2015 | J Crohns Colitis2015，9，4： | 1 |
| 15 | Prognosis of lymphoma in patients following treatment with 6‐mercaptopurine/azathioprine for inflammatory bowel disease显示文摘 | Keith Sultan Burton I. Korelitz Daniel Present Seymour Katz Suzanne Sunday Iuliana Shapira | 2012 | Inflamm Bowel Dis2012，，10： | 1 |
| 16 | Prognosis for Nonoperative Management of Small-Bowel Obstruction in Crohn?s Disease显示文摘 | Bruce H. Yaffe Burton I. Korelitz | 1983 | Journal of Clinical Gastroenterology1983，，： | 1 |
| 17 | Pregnancy in inflammatory bowel disease:effect of sulfasalazine and cortiensteroids on fetal outcome显示文摘 | Mogadam M Dobbins WO Korelitz Bl | 1981 | Gastroenterology1981，80，： | 1 |
| 18 | Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine显示文摘 | Burton I Korelitz Felice J Mirsky Mark R Fleisher Jonathan I Warman Nathaniel Wisch Gilbert W Gleim | 1999 | The American Journal of Gastroenterology1999，，11： | 1 |
| 19 | Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine 显示文摘 | Kandiel A Fraser A G Korelitz B I | 2005 | Gut2005，54，8： | 1 |
| 20 | Optimum duration of treat- ment with 6-mercaptoputine for Crohng disease显示文摘 | Kim PS Zlatanic J Korelitz BI | 1999 | Am J Gastro- enterol1999，94，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员